Logo

Autobahn Acquires Global Rights to Astellas' ASP3652 to Bolster its Brain Targeting Chemistry Platform

Share this

Autobahn Acquires Global Rights to Astellas' ASP3652 to Bolster its Brain Targeting Chemistry Platform

Shots:

  • Autobahn acquires global IP- development- and regulatory rights to ASP3652 to strengthen its brain-targeting chemistry platform. The addition of ASP3652 will accelerate the delivery of next-generation brain-targeting prodrugs for CNS disorders- particularly MS
  • ASP3652 complements Autobahn’s brain-targeting chemistry platform- which uses FAAH-mediated prodrug conversion to enable the delivery of small molecules across the BBB. The company may develop ASP3652 in combination with multiple pipeline programs- including Autobahn’s TRβ agonists for MS
  • ASP3652 is a FAAH inhibitor- previously been evaluated across 10 clinical studies in ~200 patients

  Ref: BUSINESS WIRE | Image: BioSpace

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions